EPS for Genomic Health, Inc. (GHDX) Expected At $0.01

April 22, 2018 - By Vivian Currie

Genomic Health, Inc. (NASDAQ:GHDX) LogoInvestors sentiment decreased to 1.13 in 2017 Q4. Its down 1.19, from 2.32 in 2017Q3. It fall, as 18 investors sold Genomic Health, Inc. shares while 35 reduced holdings. 18 funds opened positions while 42 raised stakes. 31.21 million shares or 1.14% more from 30.86 million shares in 2017Q3 were reported.
Zurcher Kantonalbank (Zurich Cantonalbank) reported 0% stake. Envestnet Asset accumulated 9,889 shares or 0% of the stock. Moreover, Deutsche Bancorp Ag has 0% invested in Genomic Health, Inc. (NASDAQ:GHDX). Barclays Public Ltd Limited Liability Company holds 0% of its portfolio in Genomic Health, Inc. (NASDAQ:GHDX) for 3,264 shares. Ftb Inc accumulated 890 shares. Teacher Retirement Systems Of Texas invested in 7,063 shares or 0% of the stock. California State Teachers Retirement System has invested 0% in Genomic Health, Inc. (NASDAQ:GHDX). York Cap Mngmt Global Ltd Company invested in 12,370 shares or 0.01% of the stock. Century reported 194,503 shares. State Board Of Administration Of Florida Retirement Sys has 17,659 shares for 0% of their portfolio. Spark Investment Mngmt Ltd Llc reported 82,400 shares. Baker Bros Advisors Limited Partnership invested in 4.09% or 13.78M shares. Parallax Volatility Advisers Limited Partnership holds 0% in Genomic Health, Inc. (NASDAQ:GHDX) or 2,982 shares. Voya Invest Mngmt Limited Liability Company has 0% invested in Genomic Health, Inc. (NASDAQ:GHDX). Tributary Capital Management Limited Liability Corp, a Colorado-based fund reported 318,887 shares.

Since December 12, 2017, it had 0 insider buys, and 14 insider sales for $3.89 million activity. The insider Leber Laura sold $111,080. Febbo Phillip G. sold 4,942 shares worth $162,290. Shares for $349,885 were sold by Popovits Kimberly J on Tuesday, January 16. 3,004 shares were sold by Vaughn James J, worth $102,406 on Tuesday, January 2.

Analysts expect Genomic Health, Inc. (NASDAQ:GHDX) to report $0.01 EPS on May, 8.They anticipate $0.08 EPS change or 114.29 % from last quarter’s $-0.07 EPS. GHDX’s profit would be $353,397 giving it 805.75 P/E if the $0.01 EPS is correct. After having $0.08 EPS previously, Genomic Health, Inc.’s analysts see -87.50 % EPS growth. The stock increased 0.09% or $0.03 during the last trading session, reaching $32.23. About 46,519 shares traded. Genomic Health, Inc. (NASDAQ:GHDX) has declined 2.07% since April 22, 2017 and is downtrending. It has underperformed by 13.62% the S&P500.

Genomic Health, Inc. (NASDAQ:GHDX) Ratings Coverage

Among 7 analysts covering Genomic Health (NASDAQ:GHDX), 1 have Buy rating, 3 Sell and 3 Hold. Therefore 14% are positive. Genomic Health had 9 analyst reports since November 15, 2017 according to SRatingsIntel. Canaccord Genuity maintained it with “Buy” rating and $40.0 target in Friday, March 9 report. The stock has “Buy” rating by Canaccord Genuity on Wednesday, November 15. The firm earned “Hold” rating on Thursday, March 8 by Piper Jaffray. JP Morgan downgraded the shares of GHDX in report on Wednesday, December 13 to “Underweight” rating. On Wednesday, December 20 the stock rating was downgraded by William Blair to “Hold”. The stock of Genomic Health, Inc. (NASDAQ:GHDX) has “Sell” rating given on Wednesday, December 13 by J.P. Morgan. Canaccord Genuity maintained the stock with “Buy” rating in Tuesday, January 16 report.

Genomic Health, Inc. provides actionable genomic information to personalize cancer treatment decisions worldwide. The company has market cap of $1.14 billion. It develops and commercializes genomic clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. It currently has negative earnings. The firm offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit.

Genomic Health, Inc. (NASDAQ:GHDX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.